{"id":43099,"date":"2025-10-11T15:10:37","date_gmt":"2025-10-11T07:10:37","guid":{"rendered":"https:\/\/flcube.com\/?p=43099"},"modified":"2025-10-11T15:10:38","modified_gmt":"2025-10-11T07:10:38","slug":"bms-acquires-orbital-for-1-5-b-in-rna%e2%80%91based-immunotherapy-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43099","title":{"rendered":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal"},"content":{"rendered":"\n<p><strong>Bristol-Myers Squibb (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>)<\/strong> announced today that it will acquire <strong>Orbital Therapeutics<\/strong> (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at <strong>USD\u202f1.5\u202fbillion in cash<\/strong> and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Purchase Price<\/strong> \u2013 BMS will pay <strong>USD\u202f1.5\u202fbillion<\/strong> in cash for 100\u202f% of Orbital\u2019s equity.<\/li>\n\n\n\n<li><strong>Transaction Structure<\/strong> \u2013 The agreement is a definitive acquisition with no contingent earn\u2011outs or milestone payments announced at closing.<\/li>\n\n\n\n<li><strong>Strategic Fit<\/strong> \u2013 Orbital\u2019s in\u2011vivo RNA technology aligns with BMS\u2019s focus on precision immunotherapies and offers a complementary platform to its existing CAR\u2011T and antibody programs.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-orbital-s-core-assets\">Orbital\u2019s Core Assets<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>OTX\u2011201<\/strong> \u2013 The company\u2019s lead preclinical candidate, an <strong>optimized circular RNA<\/strong> encoding a CD19\u2011targeted CAR. Delivered via <strong>targeted lipid nanoparticles (LNPs)<\/strong>, OTX\u2011201 enables the patient\u2019s own cells to produce CAR\u2011T cells <em>in vivo<\/em>, potentially reducing manufacturing complexity and improving accessibility relative to ex vivo CAR\u2011T therapies.<\/li>\n\n\n\n<li><strong>RNA Platform<\/strong> \u2013 Orbital\u2019s proprietary platform integrates <strong>circular and linear RNA engineering<\/strong>, advanced <strong>LNP delivery<\/strong>, and <strong>AI\u2011driven design<\/strong> to generate durable, programmable RNA therapeutics tailored to the biology of a wide array of diseases.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-expected-benefits\">Expected Benefits<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For BMS<\/strong> \u2013 Immediate access to a proven in\u2011vivo RNA delivery system, accelerated pipeline expansion into solid and hematologic malignancies, and a scalable platform that can be applied across multiple indications.<\/li>\n\n\n\n<li><strong>For Orbital<\/strong> \u2013 Capital infusion, global manufacturing capabilities, and a strategic partner with deep expertise in oncology drug development and commercialization.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-timeline-amp-next-steps\">Timeline &amp; Next Steps<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Regulatory Review<\/strong> \u2013 BMS will submit the acquisition to U.S. and international regulators, anticipating a standard review period.<\/li>\n\n\n\n<li><strong>Integration Planning<\/strong> \u2013 Both organizations will form a joint integration team to align clinical development, manufacturing, and commercial strategies.<\/li>\n\n\n\n<li><strong>Commercial Roll\u2011Out<\/strong> \u2013 Post\u2011approval, BMS expects to launch OTX\u2011201 in select patient populations by 2027, contingent on regulatory clearance and clinical milestones.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[428,21,77,4380],"class_list":["post-43099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-bristol-myers-squibb","tag-car-t","tag-cell-therapy","tag-orbital-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at USD\u202f1.5\u202fbillion in cash and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43099\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at USD\u202f1.5\u202fbillion in cash and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43099\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-11T07:10:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-11T07:10:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal\",\"datePublished\":\"2025-10-11T07:10:37+00:00\",\"dateModified\":\"2025-10-11T07:10:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1106.webp\",\"keywords\":[\"Bristol-Myers Squibb\",\"CAR-T\",\"Cell-therapy\",\"Orbital Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43099#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43099\",\"name\":\"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1106.webp\",\"datePublished\":\"2025-10-11T07:10:37+00:00\",\"dateModified\":\"2025-10-11T07:10:38+00:00\",\"description\":\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at USD\u202f1.5\u202fbillion in cash and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43099\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1106.webp\",\"width\":1080,\"height\":608,\"caption\":\"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43099#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at USD\u202f1.5\u202fbillion in cash and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43099","og_locale":"en_US","og_type":"article","og_title":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal","og_description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at USD\u202f1.5\u202fbillion in cash and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.","og_url":"https:\/\/flcube.com\/?p=43099","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-11T07:10:37+00:00","article_modified_time":"2025-10-11T07:10:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43099#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43099"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal","datePublished":"2025-10-11T07:10:37+00:00","dateModified":"2025-10-11T07:10:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43099"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43099#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp","keywords":["Bristol-Myers Squibb","CAR-T","Cell-therapy","Orbital Therapeutics"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43099#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43099","url":"https:\/\/flcube.com\/?p=43099","name":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43099#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43099#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp","datePublished":"2025-10-11T07:10:37+00:00","dateModified":"2025-10-11T07:10:38+00:00","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (\u201cOrbital\u201d), a privately\u2011held biotechnology company developing a next\u2011generation RNA platform that reprograms the immune system in vivo. The definitive agreement values Orbital at USD\u202f1.5\u202fbillion in cash and represents a strategic expansion of BMS\u2019s immuno\u2011oncology portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43099#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43099"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43099#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp","width":1080,"height":608,"caption":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43099#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BMS Acquires Orbital for\u202f$1.5\u202fB in RNA\u2011Based Immunotherapy Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43099"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43099\/revisions"}],"predecessor-version":[{"id":43102,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43099\/revisions\/43102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43101"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}